Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:CRDL OTCMKTS:IGXT NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$6.92+0.1%$6.80$4.66▼$7.86$113.49M0.656,410 shs3,763 shsCRDLCardiol Therapeutics$1.19$1.30$0.77▼$2.63$98.35M1.04310,202 shs345,885 shsIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AUPXIUpexi$7.48+3.3%$8.34$1.90▼$22.57$274.51M-0.581.58 million shs27.52 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences-1.99%-4.29%-0.86%+22.30%+690,999,900.00%CRDLCardiol Therapeutics-8.46%-13.14%-13.14%+17.82%-43.60%IGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%UPXIUpexi-0.28%+44.80%-24.50%+214.78%-13.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/ACRDLCardiol Therapeutics2.4554 of 5 stars3.73.00.00.02.70.00.6IGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AUPXIUpexi1.7585 of 5 stars3.51.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.6797.50% UpsideCRDLCardiol Therapeutics 3.33Buy$8.00572.27% UpsideIGXTIntelGenx Technologies 0.00N/AN/AN/AUPXIUpexi 3.00Buy$16.00113.90% UpsideCurrent Analyst Ratings BreakdownLatest IGXT, UPXI, CRDL, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.006/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$25.19M4.51N/AN/A$0.08 per share86.50CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39UPXIUpexi$26M10.91N/AN/A$6.24 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.91M-$0.50N/AN/AN/A-31.30%-307.04%-33.21%8/14/2025 (Estimated)CRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%8/11/2025 (Estimated)IGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/AUPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/29/2025 (Estimated)Latest IGXT, UPXI, CRDL, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CRDLCardiol Therapeutics-$0.11N/AN/AN/AN/AN/A5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.510.30CRDLCardiol Therapeutics0.013.263.26IGXTIntelGenx TechnologiesN/AN/AN/AUPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACRDLCardiol Therapeutics12.49%IGXTIntelGenx TechnologiesN/AUPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACRDLCardiol Therapeutics5.25%IGXTIntelGenx Technologies42.05%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.42 millionN/AN/ACRDLCardiol Therapeutics2082.65 million78.31 millionNot OptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableUPXIUpexi13037.92 million25.93 millionOptionableIGXT, UPXI, CRDL, and BHST HeadlinesRecent News About These CompaniesUpexi Shares Slump After $50M Private Placement Offering ClosesJuly 17 at 7:18 PM | marketwatch.comUpexi call volume above normal and directionally bullishJuly 17 at 7:18 PM | msn.comUpexi Shares Jump After Securing $150 Million in Convertible Notes Backed by SolanaJuly 17 at 7:18 PM | msn.comUpexi Announces Closing of $50 Million Private Placement Equity OfferingJuly 15 at 9:59 PM | manilatimes.netMUpexi Announces Closing of $50 Million Private Placement Equity OfferingJuly 15 at 8:36 AM | globenewswire.comUpexi, Inc. Announces Pricing of $200 Million Concurrent Private ...July 13, 2025 | seekingalpha.comUpexi raises $200M to boost its Solana treasuryJuly 12, 2025 | msn.comUpexi prices $200M private placement of common stock and convertible notesJuly 11, 2025 | msn.comSOL: Nasdaq-Listed Firm Secures $200M in Financing, with Over $150M Tied to Solana Treasury StrategyJuly 11, 2025 | finance.yahoo.comUpexi, Inc. Announces Pricing of $200 Million Concurrent Private Placement of Common Stock and Convertible Notes both Priced above the At-the-Market Price under Nasdaq RulesJuly 11, 2025 | globenewswire.comUpexi (NASDAQ:UPXI) Trading 26.7% Higher - Time to Buy?July 9, 2025 | marketbeat.comUpexi, Inc. (UPXI) Latest Stock News & Headlines - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening Bell | MorningstarJune 27, 2025 | morningstar.comMUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell Platform - NasdaqJune 27, 2025 | nasdaq.comSolana-Focused Upexi to Tokenize Shares; Added 56K SOL to HoldingsJune 26, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening BellJune 26, 2025 | theglobeandmail.comUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell PlatformJune 26, 2025 | quiverquant.comQUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening BellJune 26, 2025 | globenewswire.comSolana Treasury Firm Upexi Falls After Insider Sales FilingJune 25, 2025 | bloomberg.comNews Explorer — Crypto Treasury Chaos: Why Ethereum's SBET and Solana's UPXI Plunged After Routine SEC FilingsJune 25, 2025 | decrypt.coDUpexi stock plunges after filing allows investors to sell sharesJune 24, 2025 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGXT, UPXI, CRDL, and BHST Company DescriptionsBioHarvest Sciences NASDAQ:BHST$6.92 +0.01 (+0.14%) As of 03:59 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Cardiol Therapeutics NASDAQ:CRDL$1.19 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.21 +0.02 (+1.60%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.IntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Upexi NASDAQ:UPXI$7.48 +0.24 (+3.31%) Closing price 04:00 PM EasternExtended Trading$7.40 -0.08 (-1.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
